Fast Five Quiz: Recurrent/Metastatic Cervical Cancer

Sarah Ackroyd, MD, MPH


May 31, 2023

Platinum-based chemotherapy for first-line treatment of metastatic disease is considered standard of care and is recommended by both the National Comprehensive Cancer Center Network® guidelines and the European Society for Medical Oncology guidelines. Preferred regimens include platinum-based chemotherapy with a VEGF inhibitor and/or a PD-1 inhibitor (for PD-L1 positive tumors).

Biomarker testing is recommended for all tumor histology types in order to determine eligibility for pembrolizumab; only patients with PD-L1-positive tumors (CPS ≥ 1) are eligible for treatment with pembrolizumab. Monotherapy with a VEGF inhibitor is not recommended in the first-line recurrent setting owing to inferior response rates compared with combination platinum-based chemotherapy.

Learn more about the treatment of metastatic cervical cancer.

Editor's Recommendations


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.